S. C. YAZGAN Et Al. , "The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617," Prostate , vol.85, no.1, pp.90-96, 2025
YAZGAN, S. C. Et Al. 2025. The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617. Prostate , vol.85, no.1 , 90-96.
YAZGAN, S. C., Yekeduz, E., ARAZ, M., BÖLEK, H., KÜÇÜK, N. Ö., & ÜRÜN, Y., (2025). The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617. Prostate , vol.85, no.1, 90-96.
YAZGAN, SATI Et Al. "The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617," Prostate , vol.85, no.1, 90-96, 2025
YAZGAN, SATI C. Et Al. "The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617." Prostate , vol.85, no.1, pp.90-96, 2025
YAZGAN, S. C. Et Al. (2025) . "The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617." Prostate , vol.85, no.1, pp.90-96.
@article{article, author={SATI COŞKUN YAZGAN Et Al. }, title={The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617}, journal={Prostate}, year=2025, pages={90-96} }